APTA Share Price Performance
Recent APTA News & Updates
No updates
Aptahem AB (publ) Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Aug 28, 2025
- Earnings per share (EPS)
- -0.45
- Gross Margin
- 100.00%
- Net Profit Margin
- -235.59%
- Debt/Equity Ratio
- 0%
Aptahem AB (publ) Competitors
About APTA
- Founded
- 2014
- Employees
- 8
- CEO
- WebsiteView website
Aptahem AB (publ), a biotechnology company, develops and sells aptamer-based pharmaceuticals for the treatment of acute life-threatening conditions. The company’s lead products candidate is Apta-1, which is in preclinical stage to prevent the onset of life-threatening organ and tissue damage in sepsis patients. It has collaborations with various academic groups, including Consortium with Orebro University, Seattle Children’s Research Institute, and University Health Network. Aptahem AB (publ) was incorporated in 2014 and is based in Malmö, Sweden.
Swedish Market Performance
- 7 Days: -1.6%
- 3 Months: 2.8%
- 1 Year: -1.9%
- Year to Date: 0.06%
Over the last 7 days, the market has dropped 1.6%, driven by a loss of 1.4% in the Industrials sector. Overall the market has been flat in the last year. Looking forward, earnings are forecast to grow by 17% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading